[go: up one dir, main page]

MX2007014830A - Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients. - Google Patents

Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients.

Info

Publication number
MX2007014830A
MX2007014830A MX2007014830A MX2007014830A MX2007014830A MX 2007014830 A MX2007014830 A MX 2007014830A MX 2007014830 A MX2007014830 A MX 2007014830A MX 2007014830 A MX2007014830 A MX 2007014830A MX 2007014830 A MX2007014830 A MX 2007014830A
Authority
MX
Mexico
Prior art keywords
absorption
nutrients
vitamins
formulations
enhancing
Prior art date
Application number
MX2007014830A
Other languages
Spanish (es)
Inventor
Curtis A Spilburg
Original Assignee
Zomanex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zomanex Llc filed Critical Zomanex Llc
Publication of MX2007014830A publication Critical patent/MX2007014830A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method and composition of preparing bioavailable hydrophobic, poorly water soluble drugs. It uses for example, lecithin, sterol, and solvent; mixing and then the solvent driven off; the ratios used differ from others, and maximize performance.
MX2007014830A 2006-11-27 2007-11-26 Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients. MX2007014830A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/563,356 US20080124387A1 (en) 2006-11-27 2006-11-27 Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients

Publications (1)

Publication Number Publication Date
MX2007014830A true MX2007014830A (en) 2009-02-19

Family

ID=39148632

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007014830A MX2007014830A (en) 2006-11-27 2007-11-26 Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients.

Country Status (8)

Country Link
US (3) US20080124387A1 (en)
EP (1) EP1925294B1 (en)
JP (1) JP5225663B2 (en)
AU (1) AU2008203553B2 (en)
BR (1) BRPI0704205A2 (en)
CA (1) CA2612128C (en)
ES (1) ES2535076T3 (en)
MX (1) MX2007014830A (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
US20090088393A1 (en) * 2007-09-28 2009-04-02 Zomanex, Llc Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
JP2011505156A (en) * 2007-12-05 2011-02-24 ディーエスエム アイピー アセッツ ビー．ブイ． Finely pulverized preparation of fat-soluble active ingredients
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
US20110160168A1 (en) * 2009-12-31 2011-06-30 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
EP2658403B1 (en) 2010-12-29 2018-05-02 Abbott Laboratories Nutritional product for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
KR102213143B1 (en) * 2013-02-28 2021-02-08 바스프 에이에스 A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
ES2907284T3 (en) 2013-03-15 2022-04-22 Marius Pharmaceuticals Llc emulsion formulations
EP3123148B1 (en) 2014-03-31 2020-05-27 Redshift Systems Corporation Fluid analyzer with modulation for liquids and gases
US10668086B2 (en) 2014-10-17 2020-06-02 Raisio Nutrition Ltd Cholesterol lowering capsules
JP6211220B1 (en) * 2017-01-26 2017-10-11 アピ株式会社 Anthocyanin-containing composition for capsule and capsule
US12403146B2 (en) 2019-10-30 2025-09-02 Marius Pharmaceuticals, Inc. Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (en) 1977-08-05 1981-02-13 Battelle Memorial Institute
FR2416008A1 (en) 1978-02-02 1979-08-31 Oreal LIPOSOME LYOPHILISATES
FR2521565B1 (en) 1982-02-17 1985-07-05 Dior Sa Parfums Christian PULVERULENT MIXTURE OF LIPID COMPONENTS AND HYDROPHOBIC CONSTITUENTS, METHOD FOR PREPARING SAME, HYDRATED LIPID LAMELLAR PHASES AND MANUFACTURING METHOD, PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING HYDRATED LAMID PHASES
FR2534487B1 (en) 1982-10-15 1988-06-10 Dior Christian Parfums METHOD FOR THE HOMOGENEIZATION OF HYDRATED LIPIDAL LAMELLAR PHASE DISPERSIONS, AND SUSPENSIONS OBTAINED THEREBY
US4542019A (en) * 1983-03-11 1985-09-17 John Lezdey Antacid compositions
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
IT1203515B (en) * 1987-02-26 1989-02-15 Indena Spa SAPONINE COMPLEXES WITH PHOSPHOLIPIDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM
GB8714652D0 (en) * 1987-06-23 1987-07-29 Davis S S Drug emulsion
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
FR2619505B1 (en) * 1987-08-20 1990-08-31 Dior Christian Parfums COMPOSITION BASED ON HYDRATED LIPID LAMELLAR PHASES OR LIPOSOMES CONTAINING PREGNENOLONE OR A PREGNENOLONE ESTER, AND COSMETIC OR PHARMACEUTICAL COMPOSITION, IN PARTICULAR DERMATOLOGICAL, WITH REGENERATING OR REVITALIZING ACTIVITY, INCORPORATING
US5202126A (en) 1987-08-20 1993-04-13 Parfums Christian Dior Composition containing pregnenolone or a pregnenolone ester incorporated in liposomes, and a method for regenerating, or revitalizing the skin therewith
FR2623716B1 (en) * 1987-11-27 1991-04-05 Lvmh Rech COMPOSITION BASED ON HYDRATED LIPID LAMID PHASES OR LIPOSOMES CONTAINING TYROSINE OR A TYROSINE DERIVATIVE AND COSMETIC OR PHARMACEUTICAL COMPOSITION, ESPECIALLY DERMATOLOGICAL, WITH PIGMENTANT ACTIVITY, INCORPORATING IT
US5290562A (en) 1987-11-27 1994-03-01 L V M H Recherche Compositions and methods employing liposomes including tyrosine or a tyrosine derivative
US5139803A (en) 1989-02-09 1992-08-18 Nabisco, Inc. Method and liposome composition for the stabilization of oxidizable substances
WO1994012207A1 (en) * 1992-12-02 1994-06-09 Micro Vesicular Sytems, Inc. Extended duration antacid product
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
FI107015B (en) 1996-08-09 2001-05-31 Raisio Benecol Oy Composition of plant stanol fatty acid esters and its use as well as food
AU4424797A (en) * 1996-09-18 1998-04-14 Dragoco Inc. Liposome encapsulated active agent dry powder composition
KR19980030438A (en) * 1996-10-29 1998-07-25 김영환 Semiconductor Vernier structure and method of measuring overlay accuracy using it
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US6110502A (en) 1998-02-19 2000-08-29 Mcneil-Ppc, Inc. Method for producing water dispersible sterol formulations
US6087353A (en) * 1998-05-15 2000-07-11 Forbes Medi-Tech Inc. Phytosterol compositions and use thereof in foods, beverages, pharmaceuticals, nutraceuticals and the like
US5932562A (en) 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
US6063776A (en) * 1998-05-26 2000-05-16 Washington University Sitostanol formulation with emulsifier to reduce cholesterol absorption and method for preparing and use of same
US6242001B1 (en) 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
CA2382133C (en) * 2000-05-10 2010-11-23 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US20030129253A1 (en) * 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
US20030212046A1 (en) * 2002-05-07 2003-11-13 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
US20060093661A1 (en) 2002-05-07 2006-05-04 Kapac, Llc Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
MX2007008320A (en) * 2005-01-06 2007-09-07 Cima Labs Inc Taste masking system for non-plasticizing drugs.
CN103315954A (en) * 2005-07-18 2013-09-25 麻萨诸塞州洛厄尔大学 Compositions and methods for making and using nanoemulsions

Also Published As

Publication number Publication date
JP5225663B2 (en) 2013-07-03
EP1925294B1 (en) 2015-04-08
CA2612128A1 (en) 2008-05-27
ES2535076T3 (en) 2015-05-05
BRPI0704205A2 (en) 2010-09-08
CA2612128C (en) 2012-01-31
US20080124387A1 (en) 2008-05-29
US20110111009A1 (en) 2011-05-12
AU2008203553A1 (en) 2008-10-23
JP2008133281A (en) 2008-06-12
EP1925294A1 (en) 2008-05-28
AU2008203553B2 (en) 2010-10-28
US20150030671A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
MX2007014830A (en) Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients.
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
IL190646A (en) Multi-functional ionic liquid compositions comprising active pharmaceutical, biological, nutritional and energetic ingredients and method for producing the same
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
EP3002274A8 (en) Treprostinil monohydrate
WO2009043049A3 (en) Pharmaceutical formulations
WO2008037557A3 (en) Rapidly solubilising formulation of non-steroidal anti-inflammatory drugs
WO2008006715A3 (en) Improvements relating to pharmaceutical compositions
WO2006015081A3 (en) A PROCESS FOR THE PREPARATION OF 7α-ALKYLATED 19-NORSTEROIDS
WO2008030818A3 (en) Novel liposome compositions
WO2008145996A3 (en) Novel compounds and pharmaceutical preparations from neobeguea spec
EP1724278A4 (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
WO2007144169A3 (en) Entacapone-derivatives
ZA200805563B (en) Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
IL181022A0 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same
EP2279732A3 (en) Compounds and compositions for delivering active agents
WO2007016388A3 (en) Liquid formulations for controlled delivery of benzisoxazole derivatives
WO2007075825A3 (en) Lipophilic anticancer drug compounds
CA2483916A1 (en) Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
WO2007016284A3 (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form adminstration daily
EP1637167A3 (en) New injectable formulations containing progesterone
WO2005105768A3 (en) Process for preparation of mycophenolic acid and ester derivatives thereof
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
WO2007036802A3 (en) Sublingual dosage form comrising vitamin d analogue, in particular calcitriol
AU2003297367A1 (en) Process for preparing pharmaceutical formulations using supercritical fluids

Legal Events

Date Code Title Description
FC Refusal